Review on the Synthesis and Therapeutic Potential of Pyrido[2,3-], [3,2-], [3,4-] and [4,3-]pyrimidine Derivatives

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2022 Mar 26

PMID 35337149

Authors

Joana F Campos

Thierry Besson

Sabine Berteina-Raboin

Affiliations

Soon will be listed here.

Abstract

The objective of this review is to list the structures composed of a pyridopyrimidine moiety which have shown a therapeutic interest or have already been approved for use as therapeutics. We consider all the synthetic protocols to prepare these pyridopyrimidine derivatives. The review is organized into four sections, successively pyrido[2,3-]pyrimidines, pyrido[3,4-]pyrimidines, pyrido[4,3-]pyrimidines and pyrido[3,2-]pyrimidines. For each compound we present the biological activity and the synthetic route reported. To produce this manuscript, the bibliographic research was done using Reaxys and Scifinder for each kind of pyridopyrimidine.

Citing Articles

Design, Synthesis, Antimicrobial Activity, and Molecular Docking of Novel Thiazoles, Pyrazoles, 1,3-Thiazepinones, and 1,2,4-Triazolopyrimidines Derived from Quinoline-Pyrido[2,3-] Pyrimidinones.

Abu-Hashem A, Al-Hussain S Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770474 PMC: 11728477. DOI: 10.3390/ph17121632.

Combinatorial Targeting of Common Docking and ATP Binding Sites on Mps1 MAPK for Management of Pathogenic Fungi.

Kong Z, Li S, Li J, Chen Y, Chen M, Zhang X J Agric Food Chem. 2024; 72(49):27115-27124.

PMID: 39622772 PMC: 11640755. DOI: 10.1021/acs.jafc.4c09504.

New pyridopyrimidine derivatives as dual EGFR and CDK4/cyclin D1 inhibitors: synthesis, biological screening and molecular modeling.

Krakisha F, Othman D, El Husseiny W, Nasr M Future Med Chem. 2024; 16(16):1633-1648.

PMID: 39023284 PMC: 11370904. DOI: 10.1080/17568919.2024.2366147.

Antiproliferative activity of antimicrobial peptides and bioactive compounds from the mangrove .

Karthik Y, Kalyani M, Krishnappa S, Devappa R, Anjali Goud C, Ramakrishna K Front Microbiol. 2023; 14:1096826.

PMID: 36876075 PMC: 9982118. DOI: 10.3389/fmicb.2023.1096826.

Medicinal chemistry perspective of pyrido[2,3-]pyrimidines as anticancer agents.

Kumar A, Bhagat K, Singh A, Singh H, Angre T, Verma A RSC Adv. 2023; 13(10):6872-6908.

PMID: 36865574 PMC: 9972360. DOI: 10.1039/d3ra00056g.

References

Anderhub S, Mak G, Gurden M, Faisal A, Drosopoulos K, Walsh K . High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers. Mol Cancer Ther. 2019; 18(10):1696-1707. DOI: 10.1158/1535-7163.MCT-18-1203. View

Yang H, Xiang S, Kazi A, Sebti S . The GTPase KRAS suppresses the p53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cells. J Biol Chem. 2020; 295(10):3055-3063. PMC: 7062149. DOI: 10.1074/jbc.RA119.011930. View

Pearson G, Robinson F, Beers Gibson T, Xu B, Karandikar M, Berman K . Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001; 22(2):153-83. DOI: 10.1210/edrv.22.2.0428. View

Estrada-Bernal A, Le A, Doak A, Tirunagaru V, Silva S, Bull M . Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2020; 27(5):1463-1475. PMC: 7926264. DOI: 10.1158/1078-0432.CCR-20-3555. View

Hawser S, Lociuro S, Islam K . Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol. 2005; 71(7):941-8. DOI: 10.1016/j.bcp.2005.10.052. View

Wada T, Penninger J . Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 2004; 23(16):2838-49. DOI: 10.1038/sj.onc.1207556. View

Skedelj V, Arsovska E, Tomasic T, Kroflic A, Hodnik V, Hrast M . 6-Arylpyrido[2,3-d]pyrimidines as novel ATP-competitive inhibitors of bacterial D-alanine:D-alanine ligase. PLoS One. 2012; 7(8):e39922. PMC: 3410885. DOI: 10.1371/journal.pone.0039922. View

Orton R, Sturm O, Vyshemirsky V, Calder M, Gilbert D, Kolch W . Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway. Biochem J. 2005; 392(Pt 2):249-61. PMC: 1316260. DOI: 10.1042/BJ20050908. View

Kettle J, Cassar D . Covalent inhibitors of the GTPase KRAS: a review of the patent literature. Expert Opin Ther Pat. 2020; 30(2):103-120. DOI: 10.1080/13543776.2020.1709443. View

10.

Wall M, Shim J, Benkovic S . A multisubstrate adduct inhibitor of AICAR transformylase. J Med Chem. 1999; 42(18):3421-4. DOI: 10.1021/jm990323+. View

11.

Xu D, Toyoda H, Qi L, Morimoto M, Hanaki R, Iwamoto S . Induction of MEK/ERK activity by AZD8055 confers acquired resistance in neuroblastoma. Biochem Biophys Res Commun. 2018; 499(3):425-432. DOI: 10.1016/j.bbrc.2018.03.143. View

12.

Gangjee A, Vasudevan A, Queener S, Kisliuk R . 2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases. J Med Chem. 1996; 39(7):1438-46. DOI: 10.1021/jm950786p. View

13.

Gangjee A, Shi J, Queener S, Barrows L, Kisliuk R . Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents. J Med Chem. 1993; 36(22):3437-43. DOI: 10.1021/jm00074a026. View

14.

Raimondi M, Randazzo O, La Franca M, Barone G, Vignoni E, Rossi D . DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents. Molecules. 2019; 24(6). PMC: 6471984. DOI: 10.3390/molecules24061140. View

15.

Alber B . Biotechnological potential of the ethylmalonyl-CoA pathway. Appl Microbiol Biotechnol. 2010; 89(1):17-25. DOI: 10.1007/s00253-010-2873-z. View

16.

Galbraith M, Bender H, Espinosa J . Therapeutic targeting of transcriptional cyclin-dependent kinases. Transcription. 2018; 10(2):118-136. PMC: 6602565. DOI: 10.1080/21541264.2018.1539615. View

17.

Micel L, Tentler J, Tan A, Selby H, Brunkow K, Robertson K . Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. Mol Cancer Ther. 2014; 14(2):317-25. PMC: 4671492. DOI: 10.1158/1535-7163.MCT-13-1012. View

18.

Woodward H, Innocenti P, Cheung K, Hayes A, Roberts J, Henley A . Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N-(2-Ethoxy-4-(4-methyl-4 H-1,2,4-triazol-3-yl)phenyl)-6-methyl-.... J Med Chem. 2018; 61(18):8226-8240. PMC: 6166229. DOI: 10.1021/acs.jmedchem.8b00690. View

19.

Ma K, Zhang H, Baloch Z . Pathogenetic and Therapeutic Applications of Tumor Necrosis Factor-α (TNF-α) in Major Depressive Disorder: A Systematic Review. Int J Mol Sci. 2016; 17(5). PMC: 4881555. DOI: 10.3390/ijms17050733. View

20.

Anand P, Shenoy R, Palmer J, Baines A, Lai R, Robertson J . Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury. Eur J Pain. 2011; 15(10):1040-8. DOI: 10.1016/j.ejpain.2011.04.005. View